Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate Cancer

Video

In Partnership With:

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Xiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.

Following results of an increase prostate-specific antigen (PSA) score, patients undergo a systematic biopsy, known as a traditional method of diagnosing prostate cancer, Meng explains. This method is a random sampling; therefore, imaging is being used to improve the detection of localization of prostate cancer. For example, a multi-parametric MRI is a combination of anatomic and functional sequences that allow for increased localization.

From this imaging technique, each abnormality is given a suspicion score from 1 to 5, with 5 being the most likely to be cancerous, Meng explains. Practitioners then perform a MRI-US fusion targeted biopsy, which allows them to better target lesions. A recent study showed that patients with an increasing MRI suspicion score does correlate with identifying high-grade prostate cancer.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD